Calidi Biotherapeutics Q1 2026 net loss narrows to $4.4M; cash $6.6M, CLD-401 IND on track

Calidi Biotherapeutics, Inc.

2026-Q1 EPS reported -$0.43

Net loss attributable to common shareholders: $4.4M ($0.43/shr) vs $5.0M ($2.21/shr) in Q1 2025.
Cash and restricted cash $6.8M as of Mar 31, 2026; up from $5.8M at Dec 31, 2025.
G&A expenses fell $1.0M to $1.6M; R&D expenses rose to $2.6M from $2.4M.
CLD-401 IND submission expected by end of 2026; AACR data showed T, NK, and γδ T-cell activation.
Entered partnership with TransferAI to use AI platform to streamline CLD-401 IND submission.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Calidi Biotherapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income net loss attributable to common stockholders of $4.4 million, or $0.43 per share, EPS $0.43 per share.

Period: the first quarter ended March 31, 2026
Net income: net loss attributable to common stockholders of $4.4 million, or $0.43 per share
EPS: $0.43 per share
Result: reported results

Exact text from the filing

The Company reported a net loss attributable to common stockholders of $4.4 million, or $0.43 per share, for the three months ended March 31, 2026, compared to a net loss attributable to common stockholders of $5.0 million, or $2.21 per share, for the same period in 2025.

View on SEC.gov

Browse all earnings releases →

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-023094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.